Kane Biotech Inc. (CVE:KNE – Get Free Report) traded down 10.7% on Tuesday . The stock traded as low as C$0.13 and last traded at C$0.13. 113,000 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 132,867 shares. The stock had previously closed at C$0.14.
Kane Biotech Stock Down 10.7 %
The stock has a market capitalization of C$16.56 million, a PE ratio of -4.67 and a beta of 0.54. The firm has a 50 day moving average of C$0.14 and a two-hundred day moving average of C$0.14. The company has a current ratio of 0.82, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24.
Kane Biotech (CVE:KNE – Get Free Report) last released its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.62 million during the quarter.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Articles
- Five stocks we like better than Kane Biotech
- Why Invest in 5G? How to Invest in 5G Stocks
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are Dividend Challengers?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
